Rutwik Barmukh | Genetics | Innovative Research Award

Published on by Young Scientists Awards

Innovative Research Award

Rutwik Barmukh
Murdoch University, Australia

Rutwik Barmukh
Rutwik Barmukh
Affiliation Murdoch University
Country Australia
Scopus ID 57216393093
Documents 42
Citations 1,297
h-index 22
Subject Area Genetics
Event International Young Scientist Award
ORCID 0000-0002-2740-8992

The Innovative Research Award recognizes research contributions that demonstrate originality, scientific relevance, and potential impact within a specialized field. Rutwik Barmukh, affiliated with Murdoch University, Australia, is presented here in the context of research activity in genetics and scholarly publication metrics. The profile summarizes the supplied information and provides links to relevant research platforms for further verification.

Abstract

This article outlines the academic profile of Rutwik Barmukh, focusing on the supplied bibliometric indicators, institutional affiliation, and genetics subject area. The reported metrics are 42 documents, 1,297 citations, and an h-index of 22. These indicators provide a quantitative overview of scholarly output and citation activity but do not independently establish research quality or award eligibility.

Keywords

Rutwik Barmukh; genetics; research publications; citation impact; bibliometrics; scientific innovation; Murdoch University; Innovative Research Award.

Introduction

Research in genetics contributes to understanding biological variation, inheritance, and complex biological processes. Academic profiles help readers explore researchers’ publications and scholarly influence through recognized research databases. Bibliometric indicators should be interpreted alongside the relevance, methodology, originality, and reproducibility of individual studies.

Research Profile

The supplied information identifies Barmukh as affiliated with Murdoch University in Australia, with genetics listed as the subject area. The reported publication and citation statistics are provided as supplied and should be checked against the researcher’s verified database record before formal publication.

Research Contributions

Evaluating research contributions requires examining published work, the problems addressed, methodological rigor, and potential relevance to the scientific community. Specific discoveries or innovations cannot be established from bibliometric figures alone; individual publications should be reviewed to assess their contributions.

Publications

The supplied profile reports 42 documents. A complete publication list, publication titles, author details, and DOI identifiers should be retrieved from verified scholarly records. No individual publication titles or DOIs are asserted here because they were not provided.

Research Impact

The reported 1,297 citations and h-index of 22 indicate measurable citation activity in the supplied profile. Citation counts can vary between databases and over time; they should be considered alongside research quality, field-specific practices, and documented scientific or societal outcomes.

Award Suitability

The Innovative Research Award provides a context for considering originality, publication quality, and research relevance. A fair assessment of Barmukh’s suitability would require examination of verified publications, individual contributions, supporting evidence, and the award’s official evaluation criteria. The information presented does not constitute confirmation of award selection.

Conclusion

Rutwik Barmukh’s supplied profile reports scholarly activity in genetics, with 42 documents, 1,297 citations, and an h-index of 22. Verification of researcher identifiers and a qualitative review of publications are recommended before drawing conclusions about specific achievements or award suitability.

References

  1. Elsevier. (n.d.). Scopus author details: Researcher profile, Author ID 57216393093. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57216393093
  2. ORCID. (n.d.). ORCID researcher identifier and profile.
    https://orcid.org/0000-0002-2740-8992

Xingyu Chen | Cancer Biology | Young Scientist Award

Published on by Young Scientists Awards

Dr. Xingyu Chen | Cancer Biology | Young Scientist Award

Research Bioinformatician | Cedars-Sinai Medical Center | United States

Dr. Xingyu Chen is a research bioinformatician and computational oncologist specializing in sex chromosome genomics, cancer immunology, and precision medicine. His work has revealed the Loss of the Y Chromosome (LOY) as a causal driver of cancer immune evasion in men, demonstrating its role in tumor progression, immune dysfunction, and therapy resistance. He pioneered the development of the world’s first Sex Chromosome-Aware Genomic Large Language Model, integrating AI with genomic data to enhance cancer diagnostics and guide precision therapies. His research combines multi-omics analysis, single-cell and spatial transcriptomics, and deep-learning models to uncover mechanisms of tumor evolution, T-cell exhaustion, and sex-specific cancer vulnerabilities. Chen has contributed to high-impact publications in journals such as Nature, Oncogene, and International Journal of Molecular Sciences, with 800 citations, an h-index of 15, and multiple first/co-first author contributions, reflecting his influence in the field. His work extends to translational applications, including LOY-informed cellular therapies and radiogenomic predictive algorithms for bladder cancer, leading to patentable innovations. He has also mentored trainees, co-supervised projects, and collaborated with international institutions to advance integrative cancer genomics and AI-driven therapeutics. Overall, his research advances the understanding of male-biased cancer mechanisms and supports the development of innovative diagnostic and therapeutic strategies, bridging fundamental biology, computational modeling, and clinical applications to improve outcomes for men with cancer.

Featured Publications

Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., … et al. (2023). Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature, 619(7970), 624–631.

Jin, Y., Wang, Z., He, D., Zhu, Y., Chen, X., & Cao, K. (2021). Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma. Cancer Medicine, 10(23), 8693–8707.

Ayesha Ahmed | Cancer Biology | Research Excellence Award

Published on by Young Scientists Awards

Ms. Ayesha Ahmed | Cancer Biology | Research Excellence Award

Roosevelt University | United States

Ms. Ayesha Ahmed is an emerging pharmacist and pharmaceutical sciences researcher with a strong interdisciplinary foundation spanning clinical practice, pharmaceutical manufacturing, research coordination, and academic support. Her academic and professional journey reflects a commitment to advancing global healthcare through evidence-based practice, scientific inquiry, and collaborative learning. She has contributed to research projects that integrate stakeholder engagement, strategic planning, and analytical evaluation, enabling the development of targeted research approaches within the pharmaceutical and healthcare sectors. Her scientific interests encompass drug formulation, regulatory science, clinical pharmacy, and translational research aimed at improving therapeutic outcomes. She has co-authored publications exploring corrosion-resistant polymer modifications for industrial applications, barriers and enablers influencing community pharmacists’ participation in deprescribing initiatives, and molecular insights into CRP interactomes related to cellular signaling and tumorigenicity. These works demonstrate her ability to engage with both laboratory-based and clinical-conceptual research, bridging basic science with healthcare practice. She possesses strong communication and instructional skills refined through academic tutoring roles, where she supported learners in developing scientific writing, analytical reasoning, and pharmacy-related competencies. Her international training exposure has strengthened her understanding of pharmaceutical manufacturing processes, regulatory frameworks, and quality-assurance practices within diverse healthcare systems. Motivated by a passion for patient-centered care, interdisciplinary research, and global health development, she continues to expand her expertise through advanced study in pharmaceutical sciences. She aims to contribute to innovations in drug development, clinical decision-making, and pharmacy practice through research that supports safety, effectiveness, and equitable access to healthcare.

Featured Publication

Gerhardt, A., Nanakaliy, D., Shah, H. D., Sarfaraz, S., Madigan, C., Downing, M., Elliott, R. P., Dipto, R., Vrapciu, B., Noetzel, J. W., et al. (2025). Evaluating the CRP interactome: Insights into possible novel roles in cellular signaling and tumorigenicity. Current Issues in Molecular Biology, 47(12), Article 1003.

Elshazly, M., Wilkinson, J., Jawad, S., Ahmed, A., ElGeed, H., & Yusuff, K. B. (2025). Enablers and barriers to community pharmacists’ readiness to implement deprescribing of inappropriate medications for older adults in Qatar. PLOS ONE, 20(1), Article e0316363.

Azhar Mehmood | Cancer Genetics | Best Researcher Award

Published on by Young Scientists Awards

Dr. Azhar Mehmood | Cancer Genetics
| Best Researcher Award

Rawalpindi Medical University | Pakistan

Dr. Azhar Mehmood is a biochemistry and molecular biology researcher whose work spans cancer genetics, DNA damage response pathways, exosomal biomarker discovery, and infectious disease molecular diagnostics. His research contributions include extensive investigation of breast, gastric, thyroid, and head and neck cancers, with a strong emphasis on genetic polymorphisms, pathway deregulation, epigenetic mechanisms, and survival-associated molecular markers. He has explored the prognostic significance of DDR pathway genes, including ATM, ATR, Chk1, and SIRT3/FOXO3a/SOD2 regulatory axes, and conducted SNP-based risk analyses for various malignancies. His work on exosomal microRNAs—such as miR-19a/b, miR-144-3p, miR-4262, and the miR-17-92a cluster—has advanced understanding of their diagnostic and therapeutic potential in breast and brain tumors. His research background also includes contributions to molecular profiling of HCV persistence, viral immunology, and transfusion-transmitted infections. He has applied molecular techniques such as qPCR, LORD-qPCR, IHC, ELISA, genotyping, exosome characterization, and multiple biochemical assays to uncover disease mechanisms and improve diagnostic precision. His publications collectively highlight a strong focus on cancer risk assessment, biomarker identification, and translational molecular research aimed at supporting early detection, targeted therapy development, and improved patient outcomes across multiple cancer types.

Featured Publications

Haris, M. S., Hussain, M. Z., Mehmood, A., Kayani, M. A., & Mahjabeen, I. (2025). hsa-miR-144-3p and hsa-miR-4262 are exosomal biomarkers and function as tumor suppressors in HCMV positive brain tumor. Future Oncology. https://doi.org/10.1080/14796694.2025.2569097

Mehmood, A., Mahjabeen, I., Reed, S., Errington, R. J., Umar, M., Pervaiz, F., & Kayani, M. A. (2025). Association of DDR pathway proteins and breast cancer risk in a Pakistani population. Future Oncology. https://doi.org/10.1080/14796694.2025.2581508